34
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Application of Artificial Intelligence in COVID-19 drug repurposing

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background and aim

          COVID-19 outbreak has created havoc and a quick cure for the disease will be a therapeutic medicine that has usage history in patients to resolve the current pandemic. With technological advancements in Artificial Intelligence (AI) coupled with increased computational power, the AI-empowered drug repurposing can prove beneficial in the COVID-19 scenario.

          Methods

          The recent literature is studied and analyzed from various sources such as Scopus, Google Scholar, PubMed, and IEEE Xplore databases. The search terms used are ‘COVID-19′, ’ AI ′, and ‘Drug Repurposing’.

          Results

          AI is implemented in the field design through the generation of the learning-prediction model and performs a quick virtual screening to accurately display the output. With a drug-repositioning strategy, AI can quickly detect drugs that can fight against emerging diseases such as COVID-19. This technology has the potential to improve the drug discovery, planning, treatment, and reported outcomes of the COVID-19 patient, being an evidence-based medical tool.

          Conclusions

          Thus, there are chances that the application of the AI approach in drug discovery is feasible. With prior usage experiences in patients, few of the old drugs, if shown active against SARS-CoV-2, can be readily applied to treat the COVID-19 patients. With the collaboration of AI with pharmacology, the efficiency of drug repurposing can improve significantly.

          Highlights

          • With a drug-repositioning strategy, AI can quickly detect drugs that can fight against COVID-19 pandemic.

          • AI-empowered drug repurposing is a cheaper, faster, and effective approach and can reduce the failures in clinical trials.

          • AI-based Deep learning models can predict drug structures that could potentially treat COVID -19.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: not found

          Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

          Background Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads. Patients and methods French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16th, to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point. Results Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms. Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination. Conclusion Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing

            SUMMARY The novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 2.3 million people, killed over 160,000, and caused worldwide social and economic disruption 1,2 . There are currently no antiviral drugs with proven clinical efficacy, nor are there vaccines for its prevention, and these efforts are hampered by limited knowledge of the molecular details of SARS-CoV-2 infection. To address this, we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins physically associated with each using affinity-purification mass spectrometry (AP-MS), identifying 332 high-confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds). Screening a subset of these in multiple viral assays identified two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the Sigma1 and Sigma2 receptors. Further studies of these host factor targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

                Bookmark

                Author and article information

                Contributors
                Journal
                Diabetes Metab Syndr
                Diabetes Metab Syndr
                Diabetes & Metabolic Syndrome
                Published by Elsevier Ltd on behalf of Diabetes India.
                1871-4021
                1878-0334
                3 July 2020
                September-October 2020
                3 July 2020
                : 14
                : 5
                : 1027-1031
                Affiliations
                [a ]School of Applied Science, KIIT University, Bhubaneswar, Odisha, India
                [b ]Samsi Rural Hospital Rutua-1, Malda, West Bengal, India
                [c ]School of Computer Engineering, KIIT University, Bhubaneswar, Odisha, India
                [d ]School of Electronics Engineering, KIIT University, Bhubaneswar, Odisha, India
                Author notes
                []Corresponding author. chandanamohanty@ 123456gmail.com
                [∗∗ ]Corresponding author. Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Bhubaneswar, Odisha, 751024, India. swati.swayamsiddha@ 123456gmail.com
                Article
                S1871-4021(20)30237-X
                10.1016/j.dsx.2020.06.068
                7332938
                32634717
                7f744ba3-9057-4594-b92c-bab7e38b1e17
                © 2020 Published by Elsevier Ltd on behalf of Diabetes India.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 19 June 2020
                : 26 June 2020
                : 29 June 2020
                Categories
                Article

                artificial intelligence,machine learning,deep learning,covid-19,coronavirus,drug repurposing,drug repositioning

                Comments

                Comment on this article